Low macular pigment is a key modifiable risk factor for the development of age-related macular degeneration (AMD).
The MPS II is a fast, portable screener for measuring macular pigment optical density (MPOD) and monitoring its changes over time. Proven to deliver reproducible results, the MPS II is innovative and clinically relevant, enabling a preventative approach to managing the global problem of macular degeneration.
Added value for patients & practitioners
The Macular Pigment Screener (MPS II) is a key enabler in such an approach.It helps patients by identifying and monitoring macular pigment levels over time and supports professionals with the diversification of eye health services. It is:
Reliable scientifically validated through use in multiple studies
Repeatable has accurately measured more than 4 million eyes
Intuitive easy-to-use user interface with icon-driven menus
Fast screen in 90 seconds per eye for efficient patient care
Commercially viable clear ROI through test fees and suplement sales
Macular Pigment Screening
Macular pigment monitoring with the MPS II
Now eye care professionals can take a proactive, preventative approach to the growing global problem of age-related macular degeneration (AMD).
Measuring macular pigment optical density (MPOD) – a significant and modifiable risk factor for AMD – the MPS II provides results at speeds as fast as 90 seconds per eye.
“The MPS II is the quickest, most affordable, and most clinically relevant ophthalmic device in the world. It provides an efficient method for determining macular pigment optical density in everyday optometric and ophthalmological practice. I believe it will revolutionize the practice of eye care.“ Stuart P. Richer, OD, PhD
Director, Ocular Preventive Medicine
Captain James A Lovell Federal Healthcare Facility, Chicago, USA
A proactive approach to a global issue
Age-related macular degeneration (AMD) is a growing global socioeconomic threat, but there are ways to prevent or mitigate its impact. By adopting a proactive approach to fighting the condition, eye care professionals can identify and help those most at risk before more serious intervention is necessary.